

References

L-28

1. Harris LN, Ismaila N, McShane LM, et al. Use of biomarkers to guide decisions of adjuvant systemic therapy for women with early stage invasive breast cancer: American Society of Oncology clinical practice guideline. *J Clin Oncol.* 2016;(34).
1. Chen Y, Qu H, Jian M, et al. High level of serum AFP is an independent negative prognostic factor in gastric cancer. *Int J Biol Markers.* 2015;30(4): e387-e393.
2. Geng B, Liang M, Ye X, et al. Association of CA 15-3 and CEA with clinicopathological parameters in patients with metastatic breast cancer. *Mol Clin Oncol.* 2015;3(1):232-236.
3. 4. National Cancer Institute. Tumor markers. November 4, 2015.
4. 5. Holdenrieder S, Pagliaro L, Morgenstern D, Dayyani F. Clinically meaningful use of blood tumor markers in oncology. *BioMed Res Int.* 2016.
5. 6. Ducreux M, Cuhna A S, Caramella C, et al. Cancer of the pancreas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. *Ann of Onco.* 2015;26(5): 56-28.
6. 7. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. *JAMA Oncol.* 2019;5(2):173-180.
7. 8. Silvestri GA, Tanner NT, Kearney P, et al; PANOPTIC Trial Team. Assessment of plasma proteomics biomarker's ability to distinguish benign from malignant lung nodules: Results of the PANOPTIC (Pulmonary Nodule Plasma Proteomic Classifier) trial. *Chest.* 2018;154(3):491-500.